Understanding MGUS diagnosis, symptoms, and treatment is crucial for healthcare professionals. This resource provides information on MGUS ICD-10 codes (D47.2), clinical documentation requirements, and best practices for accurate medical coding. Learn about monoclonal gammopathy of undetermined significance (MGUS) diagnosis criteria, risk factors, and monitoring guidelines. Explore relevant information for physicians, nurses, medical coders, and other healthcare providers involved in the diagnosis and management of MGUS patients.
Also known as
Multiple myeloma and plasma cell neoplasms
This range includes MGUS, a precursor condition.
Monoclonal gammopathy
This code specifically identifies monoclonal gammopathy, encompassing MGUS.
Other abnormal findings of blood chemistry
MGUS may be discovered through abnormal blood protein levels.
Encounter for other preprocedural examinations
This code may be used for MGUS monitoring and surveillance.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the diagnosis Monoclonal Gammopathy of Undetermined Significance (MGUS)?
Yes
Is there an associated organ or tissue impairment?
No
Do not code MGUS. Code the diagnosed condition.
When to use each related code
| Description |
|---|
| MGUS: Elevated M protein, no symptoms/organ damage. |
| Smoldering Myeloma: Higher M protein, no CRAB criteria. |
| Multiple Myeloma: Malignant plasma cells, CRAB features present. |
Using D89.0 (MGUS, unspecified) when a more specific code like D89.1 (IgG MGUS) is clinically documented, leading to inaccurate reporting.
Miscoding MGUS (D89.0-D89.2) as multiple myeloma (C90.00-C90.09) due to similar symptoms, affecting data quality and reimbursement.
Insufficient clinical documentation to support MGUS diagnosis, impacting code assignment and potential denial of claims related to testing or monitoring.
Patient presents with a diagnosis of monoclonal gammopathy of undetermined significance (MGUS). This diagnosis is based on the presence of a serum monoclonal protein (M-protein) less than 3 g/dL, bone marrow plasma cell clonal population less than 10%, and the absence of end-organ damage related to multiple myeloma (CRAB criteria: hypercalcemia, renal insufficiency, anemia, and bone lesions). No evidence of related disorders such as amyloidosis, Waldenstrom macroglobulinemia, or lymphoma was found. The patient's M-protein isotype is [Insert IgG, IgA, IgM, IgD, or IgE] and the free light chain ratio is [Insert Kappa/Lambda ratio]. Complete blood count (CBC) and comprehensive metabolic panel (CMP) were within normal limits, except for [Specify any abnormalities]. Serum protein electrophoresis (SPEP), immunofixation electrophoresis (IFE), and urine protein electrophoresis (UPEP) confirmed the presence of the monoclonal protein. A skeletal survey was negative for lytic lesions. The patient is currently asymptomatic. The diagnosis of MGUS was discussed with the patient, including the potential risk of progression to multiple myeloma and the importance of ongoing monitoring. The plan is to monitor the patient with serial SPEP, IFE, UPEP, CBC, and CMP every [Insert frequency e.g., 6-12 months] and a skeletal survey every [Insert frequency e.g., 1-2 years]. Patient education regarding MGUS symptoms, prognosis, and monitoring was provided. Follow-up appointment scheduled in [Insert timeframe]. ICD-10 code D47.1 Monoclonal gammopathy of undetermined significance is assigned.